PTO/SB/08A (10-96)

roved for use through 10/31/99. OMB 0651-0031 hark Office; U.S. DEPARTMENT OF COMMERCE Please type a plus sign (+) inside this box → □ Patent and Tra ond to a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995. Complete if Known Substitute for form 1449A/PTO 10/054,680 Applicati n Number SUPPLEME領JAL Filing Date 01/22/02 INFORMATION DISCLOSUS First Named Inv ntor Friddle 1641 |64 Group Art Unit STATEMENT BY APPLICANT **Examiner Name** LEX-0301-USA of Attorney Docket Number Sheet

				U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite	U.S. Patent Document Number Kind Code² (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of cited Document	Pages, Columns, Lines, Where Relevant			
	No.¹			or Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear			
				,					
						·			
						· · · · · · · · · · · · · · · · · · ·			
			1						
$\neg \neg$			1 1						

	FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.¹	Foreign Patent Document			Name of Patentee or	Date of Publication of	Pages, Columns, Lines, Where Relevant			
		Office	3 Number ⁴	Kind Code⁵ (<i>if known</i>)	Applicant of Cited Document	MM-DD-YYYY Pass	Passages or Relevant Figures Appear	T⁵		
00	СК	wo	01/83744	A2	Merck Patent GMBH	11/08/01		_		
(3)	CL	wo	02/33086	A2	PE Corporation	04/25/02		 		
(3)	СМ	wo	02/46415	A2	Incyte Genomics, Inc.	06/13/02				
								_		
		I	l					L		

Examiner Signature	allila	Date Considered 8/26/03

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation designatio code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

PT	O/S	B/0	8B	(10-96)	

Approved for use through 10/31/99. OMB 0851-0031

Patent are ademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it displays a valid OMB control number. Please type a plus sign (+) inside this box → □ Under the Paperwork Reduction Act of 1995, no Complete if Known Substitute for form 1449B/PTO SUPPLEMENTAL Applicati n Number 10/054,680 Filing Dat 01/22/02 INFORMATION DISCESS Friddle First Named Inv_nt_r STATEMENT BY APPL Group Art Unit **Examiner Name**

Attorney Docket Number

LEX-0301-USA

2

Sheet

2

of

	0:1-	OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
xaminer nitials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
<i>S</i>	GN-	Database EMBL 'Online', KBAFV A.S., "Homo sapions partial SCL8A3 gene for solute carrier family 8 (sedium/calcium-exchanger), member 3 (SCL6A3), exon 2", 11/29/95, Database assession no. X90107, XP002222020—	
	СО	KRAEV, et al., "The organization of the Human Gene NCX1 Encoding the Sodium-Calcium Exchanger," Genomics, Vol. 37, 1996, pgs. 105-112	_
	СР	Database EMBL 'Online', NICOLL, D.A., "Rattus norvegicus sodium-calcium exchanger form 3 (NXC3) mRNA, complete cds," 09/23/96, Database accession no. U53420, XP002222324	_
	cq	NICOLL, et al., "Cloning of a third mammalian Na+-Ca2+ exchanger, NCX3," J. Biol. Chem., Vol. 271, No. 40, 1996, pgs. 24914-24921	_
	GN-	Database EMBL 'Online', SOKOLOW, 3., "Mus musculus esdium-salcium exchanger 3 (slc8a3) mRNA, partial cds;" 12/31/00; Database assession no. AE321404, XP002222325	_
	68	Database EMBL 'Online', LEE stal., "Sequense 41 from patent WO0246415," 08/12/02, Database accession no AX480881, XP002223181	
	OT	Batabase EMBL 'Online', BORTOLUZZI, 9, "Home capions mRNA for sedium/calcium exchanger, SCL8A6, alternative—splice form B (SCL8A2 gene)," 06/06/01, Database accession no. AJ304854, XP002222548.	
T	6U -	Database Swiss-Prot, 'Online', "Sodium/calcium exchanger 3 percursor (Na(+)/Ca(2+)-exchange protein 3) (fragment)," 10/15/01, Database accession no. P57103, XP002223039	
<i>S</i>	cv	GABELLINI, et al., "The human SLC8A3 gene and the tissue-specific Na+/Ca2+ exchanger 3 isoforms," Gene, Vol. 298, 09/18/02, pgs. 1-7, XP002223204	-
BU		International-Search Report, International Application No. PCT/US02/01017, 01/22/02 (Attorney Docket No. LEX-0301—POT)	
			-
			L
			\vdash
			L

Examiner Date Considered Signature

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.